Bronchoalveolar Lavage Fluid in Scleroderma Interstitial Lung Disease: Technical Aspects and Clinical Correlations: Review of the Literature

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 1, 2010, Pages 73-88

  Kowal Bielecka, Otylia ^a   Kowal, Krzysztof ^a   Highland, Kristin B ^b   Silver, Richard M ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bronchoalveolar lavage; Interstitial lung disease; Scleroderma

Indexed keywords

ANTIMALARIAL AGENT; CYCLOPHOSPHAMIDE; PENICILLAMINE; PLACEBO; STEROID;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DISEASE SEVERITY; EOSINOPHIL; FIBROBLAST CULTURE; HUMAN; INFORMATION RETRIEVAL; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG FUNCTION TEST; LUNG LAVAGE; LYMPHOCYTE; MEDLINE; METHODOLOGY; MYOFIBROBLAST; NEUTROPHIL; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SCLERODERMA; SCORING SYSTEM; SUPERNATANT; SYSTEMIC SCLEROSIS; COMPLICATION; DIFFERENTIAL DIAGNOSIS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC;

BRONCHOALVEOLAR LAVAGE FLUID; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES, INTERSTITIAL; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC;

EID: 77955271630     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.10.009     Document Type: Review

References (51)

1. Technical recommendations and guidelines for bronchoalveolar lavage (BAL) report of the European Society of Pneumology Task Group on BAL. Eur Respir J 1989, 2:561-585.
2. Goldstein R.A., Rohatgi P.K., Bergofsky E.H., Block E.R., Daniele R.P., Dantzker D.R., et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 1990, 142:481-486.
3. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990, 141:S169-S202. The BAL Cooperative Steering Committee.
4. Baughman R.P. Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Sem Respir Crit Care Med 2007, 28:475-485.
5. Haslam P.L., Beughmann R.P. Report of ERS Task Force: guidelines for measurement of acellular components and recommendations for standardization of BAL. Eur Respir J 1999, 14(2). (eds).
6. Silver R.M., Metcalf J.F., Stanley J.H., LeRoy E.C. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum 1984, 27:1254-1262.
7. Silver R.M., Miller K.S., Kinsella M.B., Smith E.A., Schabel S.I. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990, 88:470-476.
8. Konig G., Luderschmidt C., Hammer C., Adelmann-Grill B.C., Braun-Falco O., Fruhmann G. Lung involvement in scleroderma. Chest 1984, 85:318-324.
9. Harrison N.K., Glanville A.R., Strickland B., Haslam P.L., Corrin B., Addis B.J., et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989, 83:403-414.
10. Harrison N.K., McAnulty R.J., Haslam P.L., Black C.M., Laurent G.J. Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis. Thorax 1990, 45:606-610.
11. Frigieri L., Mormile F., Grilli N., Mancini D., Ciappi G., Pagliari G., et al. Bilateral bronchoalveolar lavage in progressive systemic sclerosis: interlobar variability, lymphocyte subpopulations, and functional correlations. Respiration 1991, 58:132-140.
12. Remy-Jardin M., Remy J., Wallaert B., Bataille D., Hatron P.Y. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993, 188:499-506.
13. Wells A.U., Hansell D.M., Rubens M.B., Cullinan P., Haslam P.L., Black C.M., et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994, 150:462-468.
14. Behr J., Vogelmeier C., Beinert T., Meurer M., Krombach F., Konig G., et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996, 154:400-406.
15. Witt C., Borges A.C., John M., Fietze I., Baumann G., Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999, 58:635-640.
16. White B., Moore W.C., Wigley F.M., Xiao H.Q., Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
17. Giacomelli R., Valentini G., Salsano F., Cipriani P., Sambo P., Conforti M.L., et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002, 29:731-736.
18. Kim D.S., Yoo B., Lee J.S., Kim E.K., Lim C.M., Lee S.D., et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:121-127.
19. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581-1586.
20. Clements P.J., Goldin J.G., Kleerup E.C., Furst D.E., Elashoff R.M., Tashkin D.P., et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004, 50:1909-1917.
21. Kowal-Bielecka O., Kowal K., Rojewska J., Bodzenta-Lukaszyk A., Siergiejko Z., Sierakowska M., et al. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005, 64:1343-1346.
22. De Santis M., Bosello S., La Torre G., Capuano A., Tolusso B., Pagliari G., et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005, 6:96.
23. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
24. Goh N.S., Veeraraghavan S., Desai S.R., Cramer D., Hansell D.M., Denton C.P., et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007, 56:2005-2012.
25. Mittoo S., Wigley F.M., Wise R., Ciao H., Hummers L. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis Rheum 2007, 56:4195-4202.
26. Strange C., Bolster M.B., Roth M.D., Silver R.M., Theodore A., Goldin J., et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008, 177:91-98.
27. Valentini G., Silman A.J., Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003, 21(3 Suppl 29):S39-S41.
28. Kowal-Bielecka O., Kowal K., Rojewska J., Lewszuk A., Bodzenta-Lukaszyk A., Walecki J., et al. Interleukin-8 in bronchoalveolar lavage fluid of patients with scleroderma lung disease treated with cyclophosphamide. Ann Rheum Dis 2005, 64(Suppl III):284.
29. Kowal-Bielecka O., Distler O., Kowal K., Siergiejko Z., Chwiecko J., Sulik A., et al. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum 2003, 48:1639-1646.
30. Daniil Z.D., Gilchrist F.C., Nicholson A.G., Hansell D.M., Harris J., Colby T.V., et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999, 160:899-905.
31. Travis W.D., Matsui K., Moss J., Ferrans V.J. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000, 24:19-33.
32. Nicholson A.G., Colby T.V., du Bois R.M., Hansell D.M., Wells A.U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000, 162:2213-2217.
33. Park J.H., Kim D.S., Park I.N., Jang S.J., Kitaichi M., Nicholson A.G., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175:705-711.
34. Ludwicka A., Trojanowska M., Smith E.A., Baumann M., Strange C., Korn J.H., et al. Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of scleroderma patients. J Rheumatol 1992, 19:1716-1723.
35. Scheja A., Larsen K., Todorova L., Tufvesson E., Wildt M., Akesson A., et al. BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis. Eur Respir J 2007, 29:446-452.
36. Shi-Wen X., Denton C.P., McWhirter A., Bou-Gharios G., Abraham D.J., du Bois R.M., et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum 1997, 40:1237-1244.
37. Tourkina E., Gooz P., Pannu J., Bonner M., Scholz D., Hacker S., et al. Opposing effects of protein kinase C α and protein kinase C α on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005, 280:13879-13887.
38. Wang X.M., Zhang Y., Kim H.P., Zhou Z., Feghali-Bostwick C.A., Liu F., et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006, 203:2895-2906.
39. Tourkina E., Richard M., Gooz P., Bonner M., Pannu J., Harley R., et al. Anti-fibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Pathol Lung Cell Mol Physiol 2008, 294:L843-L861.
40. Kinsella M.B., Smith E.A., Miller K.S., LeRoy E.C., Silver R.M. Spontaneous production of fibronectin by scleroderma alveolar macrophages. Arthritis Rheum 1989, 32:577-583.
41. Pantelidis P., McGrath D.S., Southcott A.M., Black C.M., du Bois R.M. Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific. Respir Res 2001, 2:365-372.
42. Atamas S.P., Yurovsky V.V., Wise R., Wigley F.M., Goter Robinson C.J., Henry P., et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42:1168-1178.
43. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Choi J., Xiao H.Q., et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 2003, 48:2262-2274.
44. Ludwicka A., Ohba T., Trojanowska M., Yamakage A., Strange C., Smith E.A., et al. Elevated levels of TGF-1 and PDGF in scleroderma bronchoalveolar lavage fluid. J Rheumatol 1995, 22:1876-1883.
45. Bolster M.B., Ludwicka A., Sutherland S.E., Strange C., Silver R.M. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:743-751.
46. Meloni F., Caporali R., Bianco M., Paschetto E., Morosini M., Fietta A.M., et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:111-118.
47. Atamas S.P., Luzina I.G., Choi J., Tsymbalyuk N., Carbonetti N.H., Singh I.S., et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003, 29:743-749.
48. Kowal-Bielecka O., Kowal K., Distler O., Rojewska J., Bodzenta-Lukaszyk A., Michel B.A., et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005, 52:3783-3791.
49. Bogatkevich G.S., Ludwicka-Bradley A., Highland K.B., Hant F., Nietert P.J., Singelton C.B., et al. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum 2007, 56:2432-2442.
50. Flaherty K.R., Travis W.D., Colby T.V., Toews G.B., Kazerooni E.A., Gross B.H., et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001, 164:1722-1727.
51. Kinder B.W., Brown K.K., Schwarz M.I., Ix J.H., Kervitsky A., King T.E. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008, 133:226-232.